ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,557.81
0.28%
Dow Jones
44,713.52
-0.31%
Gold vs US Dollar
2,760.085
0.00%
Brent Oil
75.775
-0.19%
Bitcoin
104,051.20
0.30%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
27/01/202523:00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapiesNASDAQ:AZNAstraZeneca PLC
27/01/202510:45PR Newswire (US)Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
23/01/202519:33PR Newswire (Canada)AstraZeneca prévoit un investissement de 820 M$ CA (570 M$ US) au Canada pour consolider son statut grandissant de plaque tournante mondiale et faire progresser la réalisation d'essais cliniquesNASDAQ:AZNAstraZeneca PLC
23/01/202519:32PR Newswire (Canada)AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical deliveryNASDAQ:AZNAstraZeneca PLC
23/01/202510:45PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
23/01/202510:00PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
20/01/202510:45PR Newswire (US)The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZNNASDAQ:AZNAstraZeneca PLC
17/01/202522:35Business WireDATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
17/01/202512:00Business WireCALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphomaNASDAQ:AZNAstraZeneca PLC
16/01/202510:45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
13/01/202512:00Business WireDatopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
13/01/202510:45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
09/01/202510:45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AZNAstraZeneca PLC
02/01/202518:50PR Newswire (US)AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZNNASDAQ:AZNAstraZeneca PLC
02/01/202515:42PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
30/12/202410:45PR Newswire (US)Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact The Gross Law FirmNASDAQ:AZNAstraZeneca PLC
18/12/202414:05PR Newswire (Canada)Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform nNASDAQ:AZNAstraZeneca PLC
18/12/202414:05PR Newswire (Canada)Alexion, la division des maladies rares d'AstraZeneca, et l'Alliance pharmaceutique pancanadienne (APP) parviennent à un accord au sujet de Koselugo (sélumétinib) pour le traitement des enfants atteints de neurofibromatose de type 1 (NF1) présentant deNASDAQ:AZNAstraZeneca PLC
11/12/202415:15Business WireLYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trialNASDAQ:AZNAstraZeneca PLC
09/12/202412:00Business WireDatopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
08/12/202416:00Business WireFixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trialNASDAQ:AZNAstraZeneca PLC
06/12/202412:00Business WireIMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancerNASDAQ:AZNAstraZeneca PLC
05/12/202412:13Business WireIMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancerNASDAQ:AZNAstraZeneca PLC
05/12/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
04/12/202414:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
02/12/202415:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
02/12/202415:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
25/11/202412:00Business WireTRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trialNASDAQ:AZNAstraZeneca PLC
25/11/202411:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
20/11/202416:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Your Recent History

LSE
DGE
Diageo
LSE
GGP
Greatland Gold
LSE
ALBA
Alba Mineral Resources
LSE
RR.
Rolls-royce
LSE
TW.
Taylor Wimpey
LSE
AGL
Angle
LSE
TSCO
Tesco
LSE
BARC
Barclays
LSE
MAST
Mast Energy Developments
LSE
PRD
Predator Oil & Gas
LSE
GBP
Global Petroleum
LSE
SHEL
Shell
LSE
BKS
Beeks Financial Cloud
LSE
AJB
Aj Bell
LSE
LIT
Litigation Capital Manag...
LSE
TSLA
1x Tsla
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads